Subcortical vascular dementia: Survey of treatment patterns and research considerations

Canadian Journal of Neurological Sciences

Volumn 25, Issue 4, 1998, Pages 320-324

  Molnar, Frank J ^a,b   Man Son Hing, Malcolm ^b,f   John, Phil St ^c,h   Brymer, Chris ^d,g   Rockwood, Kenneth ^e   Hachinski, Vladimir ^f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c Section of Nuclear Medicine   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Division of Geriatric Medicine   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h Department of Clinical Neurological Sciences ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; TICLOPIDINE; WARFARIN;

ARTICLE; CANADA; DRUG EFFICACY; HEALTH SURVEY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDICAL SPECIALIST; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0031739758     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100034351     Document Type: Article

References (29)

1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-479.
2. Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995; 14: 240-257.
3. Rockwood K, Parhad I, Hachinski V, et al. Diagnosis of vascular dementia: Consortium of Canadian Centres for Clinical Cognitive Research consensus statement. Can J Neurol Sei 1994; 21: 358-364.
4. Amar K, Wilcock GK, Scott M. The diagnosis of vascular dementia in the light of the new criteria. Age Aging 1996; 25: 51-55.
5. Verhey F, Lodder J, Rozendaal N, Jolies J. Comparison of seven sets of criteria used for the diagnosis of vascular dementia. Neuroepidemiology 1996; 15: 166-172.
6. Amar K, Wilcock G. Vascular dementia. 1996; 312: 227-231.
7. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment.Br Med J 1994; 296: 320-331.
8. Antiplatelet Trialis' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. B. Med J 1994; 308: 81-106.
9. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischémie stroke. N Engl J Med 1995; 332: 238-248.
10. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
11. Gent M, Easton JD, Hachinski VC, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 3: 1215-1220.
12. Meyer JS, Judd BW, Tawakina T, et al. Improved cognition after control of risk factors for multi-infarct dementia. JAMA 1986; 256: 2203-2209.
13. Meyer JS, Roger KL, McClintic KL, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. J Am Geriatr Soc 1989; 37: 549-555.
14. Meyer JS, Obara K, Muramatsu K, et al. Cognitive performance after small strokes correlates with ischemia, not atrophy of the brain. Dementia 1995; 6:312-322.
15. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, eds. Geriatric Psychiatry: a Handbook for Psychiatrists and Primary Care Physicians. New York: Grune and Stratton, 1976.
16. Rockwood K. Lessons from mixed dementia. International Psychogeriatrics (in press).
17. Rother M, Kittner B, Rudolphi K, Rossner M, Labs KH. HWA 285 (propentofylline) a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Ann NY Acad Sei 1996; 777: 404-409.
18. Erkinjuntii T. Clinical criteria for vascular dementia: The NINDS -AIREN criteria. Dementia 1994; 5:189-192.
19. Wallin A, Blennow K. The clinical diagnosis of vascular dementia. Dementia 1994; 5: 181-184.
20. Mohr E, Feldman H, Gauthier S. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Can J Neurol Sei 1995; 22: 62-71.
21. Bergman H, Chertkow H, Wolfson C, et al. HM-POA (CERETEC) SPECT brain scanning in the diagnosis of Alzheimer's disease. J Amer Geriatr Soc 1997; 45: 15-20.
22. Folstein MF, Folstein SE, McHugh PR. Mini-mental state, a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
23. Teng EL, Chui HC. The Modified Mini-mental State (3MS) Examination. J Clin Psychiatr 1991; 48: 314-318.
24. McDowell I, Kristjansson B, Hill GB, Hebert R. Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-mental State Exam compared. J Clin Epidemiol 1997; 50: 377-383.
25. Rosen WO, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr 1984; 141:1356-1364.
26. Hachinski VC, Iliff LD, Iliff MP. Cerebral blood How in dementia. Arch Neurol 1975; 32: 632-637.
27. American Psychiatric Association. Diagnostic and Statistical Manual, 3rd ed. Revised. Washington: American Psychiatric Association, 1987.
28. Roman GC, Tatemichi TK, Erkinjuntii T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260.
29. Chui HC, Victoroff JI, Margolin D, et al. Criteria for the diagnosis of ischémie vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centres. Neurology 1992; 42: 473-480.